IND for SON-1010 cleared by FDA with first patient dosed in trial for advanced solid tumors SON-080 on track to begin clinical studies by mid-2022 Preclinical data for SON-1010, SON-1210, and SON-1410 presented at the 2022 AACR Annual Meeting Preclinical development of additional FHAB pipeline assets […]